Search results
Showing 76 to 90 of 125 results for hepatitis
FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care (DG48)
Evidence-based recommendations on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care
Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)
Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin (Copegus) for treating chronic hepatitis C in children and young people.
Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making
This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.
NICE responds to failure of talks to reach price agreement on Enhertu
Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged.
Learning disability: care and support of people growing older (QS187)
This quality standard covers identifying, assessing and regularly reviewing the care and support needs of people with a learning disability as they grow older. People with a learning disability have many of the same age-related health and social care needs as other people, but this quality standard focuses on the specific challenges associated with their learning disability. It describes high-quality care in priority areas for improvement.
View quality statements for QS187Show all sections
Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems)
Integrated health and social care for people experiencing homelessness (NG214)
This guideline covers providing integrated health and social care services for people experiencing homelessness. It aims to improve access to and engagement with health and social care, and ensure care is coordinated across different services.
The guidance has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.
Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis in adults.
and cost effectiveness of hepatitis B surface antigen (HBsAg) quantitative assays in determining treatment duration in...
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
This guidance has been withdrawn because Bristol-Myers Squibb has discontinued daclatasvir (Daklinza).
Cellulitis and erysipelas: antimicrobial prescribing (NG141)
This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use and reduce antibiotic resistance.